Search News + Media

Fedex dropped off a small box full of big hopes at Melrose-Wakefield Hospital Tuesday morning.“This is truly the answer we’ve been waiting for,” said Dr. Steven Sbardella, the hospital’s Chief Medical Officer.

Tufts Medical Center announced today that it has become the first center in New England to use the drug Jelmyto (UroGen Pharma, Inc.) for treatment of upper tract urothelial cancer (UTUC), a malignancy found in the kidney lining or the ureter, the thin tube connecting the bladder to the kidneys.

The COVID-19 pandemic has been a stressful time for healthcare workers everywhere. But at MelroseWakefield Hospital, creative and proactive thinking by experienced and highly skilled staff throughout the organization has led to new levels of innovation to respond to the challenges.